Additionally, small molecule drugs, due to their simple structure, easy synthesis, and low cost, have a broad application prospect in metabolic disease treatment and are becoming a hot topic for pharmaceutical companies
Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss
Again, these peptides are not FDA-approved and fall under Category 2, meaning they are legally limited to research settings and are not officially sanctioned for medical treatment
People undergo gene mutation every day for all sorts of benign reasons, so tracing one gene mutation to one particular cause is incredibly difficult
For people with T2D, a phase 2 trial showed that 12 weeks of efinopegdutide achieve up to 7.9% WL (compared to 0.7% WL with placebo) without actual improvement in HbA1c [78]
Uchimura Y et al